Recruiting
Phase 2

AMX0035

Sponsor:

University of Washington

Code:

NCT07699380

Conditions

Type 1 Diabetes (T1D)

Metabolic Diseases

Glucose Metabolism Disorders

Endocrine System Diseases

Autoimmune Diseases

Eligibility Criteria

Sex: All

Age: 18 - 69

Healthy Volunteers: Not accepted

Interventions

AMX0035

Placebo

Study Details

Brief summary:

The study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per arm). Enrollment will be distributed equally between the University of Washington and Amsterdam University Medical Center/Diabetes Center Amsterdam. Participants will be recruited through diabetes research registries, local T1D clinics, and community outreach.

Conditions

Type 1 Diabetes (T1D)

Metabolic Diseases

Glucose Metabolism Disorders

Endocrine System Diseases

Autoimmune Diseases

Study ID

NCT07699380

Start date

Jun, 2026

Status verified date

May, 2026

Completion date

Dec, 2029

Anticipated

Primary completion date

Dec, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 69

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Adults ≥18 years to <70 years of age with established T1D (duration ≥1 year)
2. Currently on insulin therapy (multiple daily injections or insulin pump)
3. HbA1c <9.5%
4. BMI 18.5-40 kg/m2
5. On stable dose of RASB or statin, if indicated
6. Willing and able to comply with all study procedures

Exclusion Criteria:

1. History of pancreatic disease (including pancreatitis) or pancreatic surgery
2. History of cardiovascular disease or stroke within the past 6 months
3. History of heart failure per New York Heart Association criteria
4. History of severe edema or salt restriction requirement
5. Biliary disease or pathologies that may alter enterohepatic circulation of bile acids
6. Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m²
7. Liver disease (ALT/AST >3x upper limit of normal \[ULN\])
8. Pregnancy, breastfeeding, or planning pregnancy during the study period
9. Known hypersensitivity to study drug components
10. Abnormal baseline ECG
11. Use of off label medications that affect insulin sensitivity within the past 1 month (e.g., metformin, GLP-1RA, SGLT2i, pioglitazone)
12. Chronic use of anticoagulants
13. Use of bile acid sequestering agents, inhibitors of bile acid transporters, bile acid derivatives, aluminum-based antacids, probenecid, pan-HDAC inhibitors, phase 2 metabolizing enzymes (e.g., uridine diphosphate glucuronosyl transferases), phase 1 metabolizing enzymes other than cytochrome P450 enzymes (CYPs), and OATP1B3
14. Use of substrates of CYP1A2, CYP2C8, CYP2B6, CYP3A4, Organic Anion transporter 1, P-glycoprotein, and Breast Cancer Resistance Protein
15. History of severe hypoglycemia requiring assistance within the past 3 months
16. History of diabetic ketoacidosis (DKA) within the past 3 months
17. Personal or family history of breast cancer or ovarian cancer
18. Current participation in another clinical trial
19. Any condition(s) found by the study team and confirmed with the Investigator that make it unsafe to participate

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: AMX0035

Participants will be instructed to take one packet of AMX0035 daily for the first 2 weeks, followed by 1 packet twice a day (morning and evening) thereafter for \~6 months.

placebo comparator: Placebo

Participants will be instructed to take one packet of placebo daily for the first 2 weeks, followed by 1 packet twice a day (morning and evening) thereafter for \~6 months.

Interventions

AMX0035

AMX0035 sachets

Placebo

Placebo sachets

Primary outcome measure

  • Change in whole-body insulin sensitivity (M-value) measured by hyperinsulinemic-euglycemic clamp [ Time Frame: Baseline, 24 weeks ]

Central Contacts and Locations

Central contacts

Amanda Bard, MMS, MS, CCRC

206-685-2069abard@uw.edu

Locations

University of Washington Medicine Diabetes Institute (UWMDI)

Recruiting

Seattle, Washington, United States, 98109

Contacts

Amanda Bard, MMS, MS, CCRC

206-685-2069abard@uw.edu

Principal Investigator:

Petter Bjornstad, MD

More Information

Sponsor

University of Washington

Last update posted

Jul 13, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Washington on 2026-07-13.